Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females

Cost Effectiveness and Resource Allocation

Volumn 13, Issue 1, 2015, Pages

  Olsen, Jens ^a,b   Jørgensen, Tine Rikke ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Incentive ^*  (Denmark)

Author keywords

Cancer; Cost effectiveness; Gender neutral vaccination; Genital warts; HPV related diseases; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGED; ANUS CANCER; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPOPHARYNX CANCER; IMMUNIZATION; LARYNX CANCER; MALE; MOUTH CANCER; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VULVA CANCER;

EID: 84924577859     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-015-0029-9     Document Type: Article

References (35)

1. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157-64.
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32.
3. Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
4. WHO International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Human Papillomavirusses. Volume 90. 2007.
5. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S3/11-25.
6. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26 Suppl 10:K17-28.
7. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124:2375-83.
8. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53 Suppl 1:S12-21.
9. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009;62:870-8.
10. De VH, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626-36.
11. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-75.
12. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24 Suppl 3:S35-41.
13. Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;26:4513-8.
14. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
15. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010;26(2):183-91.
16. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845-52.
17. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41.
18. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858-67.
19. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.
20. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.
21. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27:5133-41.
22. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443-50.
23. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30:6016-9.
24. Olsen J, Jørgensen TR, Kofoed K, Larsen HK. Incidence and cost of anal, penile, vaginal and vulva cancer in Denmark. BMC Public Health. 2012;17(1082):1-7.
25. Olsen J, Jorgensen TR, Rubek N. The economic burden of head and neck cancers in Denmark. Int J Otolaryngol Head Neck Surg. 2013;2:103-9.
26. Statens Serum Institut. The Cancer Register. Statistics and analyses [Cancerregisteret. Tal og analyse]. Copenhagen. 2012.
27. National Board of Health. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment; 2007 Jan.
28. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine. 2008;26:5654-61.
29. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343:d5775.
30. Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163:534-43.
31. Sørensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health. 2009;37:467-74.
32. Statens Serum Institut. EPI-news. Surveillance and prevention of infectious diseases. Revision of the HPV vaccination program for 12 6 13 years old girls. 2014, week 28-32. [EPI-nyt. Overvågning og forebyggelse af smitsomme sygdomme. Ændring af HPV-vaccinationsprogrammet for 12-og 13-årige piger. 2014, Uge 28-32]. Copenhagen. 2014.
33. Statens Serum Institut. EPI-news. Surveillance and prevention of infectious diseases. HPV vaccination - vaccination coverage 2012. Week 20-2013 [EPI-NYT. Overvågning og forebyggelse af smitsomme sygdomme. HPV-vaccination - tilslutning 2012. Uge 20-2013]. Copenhagen. 2013.
34. Australian Government. National Immunisation Program Schedule [Internet]. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/4CB920F0D49C61F1CA257B2600828523/$File/nip-schedule-card-hib-menc-update.pdf. 2013. Available from:
35. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:1447-54.